Endocrine Disorders and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review

Area of Science:

• Endocrinology
• Hepatology
• Metabolic Diseases

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health issue, affecting approximately 25% of the population.
• MASLD is the liver's manifestation of systemic metabolic dysregulation, closely associated with type 2 diabetes, cardiovascular diseases, and malignancies.
• The liver interacts intricately with endocrine pathways, including thyroid, sex hormone, and growth hormone signaling, influencing MASLD pathophysiology.

Purpose of the Study:

• To review the complex interplay between MASLD and endocrine disorders.
• To elucidate the underlying pathophysiological mechanisms driving these interactions.
• To highlight novel therapeutic strategies for MASLD in the context of endocrine dysfunction.

Main Methods:

• Literature review synthesizing current research on MASLD and endocrine system interactions.
• Analysis of pathophysiological mechanisms linking metabolic dysregulation and liver disease.
• Identification of emerging treatment paradigms.

Main Results:

• MASLD pathophysiology is multifactorial, ranging from simple steatosis to cirrhosis.
• Prevalence is increasing due to lifestyle factors and endocrine disturbances.
• MASLD frequently co-occurs with various endocrinopathies, necessitating integrated management.

Conclusions:

• The relationship between MASLD and endocrine disorders is critical for clinical management.
• Further research into this intersection is vital for improving diagnostic accuracy and therapeutic outcomes.
• Understanding endocrine crosstalk offers promising avenues for future MASLD research and treatment.